TQB2858

Overview

TQB2858 is an investigational bispecific antibody co-targeting PDCD1 (PD-1) and CD276 (B7-H3). It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors, exploiting B7-H3 overexpression in NPC.

Evidence in the corpus

• TQB2858 bispecific PD-1×B7-H3 antibody listed as an investigational agent for NPC; B7-H3 (CD276) is overexpressed in NPC and targeted both by ADC YL201 (ORR 48.6% in NPC, n=70) and by bispecific checkpoint approaches PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.